No Data
No Data
Dyadic International Strikes Major Biotech Deal With Proliant
Dyadic International Secures Lucrative Biotech Licensing Deal
Express News | Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation
Dyadic Dips on New Partnership With Proliant
Dyadic International, Inc. and Proliant Health and Biologicals Announce Recombinant Albumin Development and Commercialization Partnership
JUPITER, Fla., June 28, 2024 — Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health
Form 144 | Dyadic(DYAI.US) 10% Stockholder Proposes to Sell 657.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 6, $Dyadic(DYAI.US)$ 10% Stockholder Francisco Trust under agreement dated February 28, 1996 intends to sell 292.4K shares of its common stock on Jun 6, with a total market